News & Media
Forge Therapeutics awarded up to $17.2 million by NIH/NIAID for FG-LpxC, a novel antibiotic to treat antimicrobial resistance (AMR)
San Diego, California, September 29, 2022 – Forge Therapeutics, Inc. (Forge), a biotechnology company ...
Forge Therapeutics achieves CARB-X milestone for FG-LpxC LUNG antibiotic program
San Diego, California, September 22, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company ...
Forge Therapeutics appoints Andrew Tomaras, Ph.D. as Chief Scientific Officer
San Diego, California, June 3, 2021 – Forge Therapeutics, Inc. (Forge), a biotechnology company ...
Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 ...
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug ...
